Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2022 Aug 16;12:985507. doi: 10.3389/fonc.2022.985507

Corrigendum: Post-operative complications and nipple necrosis rates between conventional and robotic nipple-sparing mastectomy

Jeea Lee 1, Hyung Seok Park 1,*, Haemin Lee 1, Dong Won Lee 2, Seung Yong Song 2, Dae Hyun Lew 2, Jee Ye Kim 1, Seho Park 1, Seung Il Kim 1
PMCID: PMC9425093  PMID: 36052253

In the published article, there was an error in Table 2 as published. The margin status of pathology in the table was 240 (96.8%) in the CNSM group and 32 (94.1%) in the RNSM group (p = 0.404). The correct values of margin status are 245 (98.8%) in the CNSM group and 33 (97.1%) in the RNSM group (p = 0.423). The corrected Table 2 Surgical methods and post-operative outcomes and its caption “Surgical methods and post-operative outcomes” appear below.

Table 2.

Surgical methods and post-operative outcomes.

CNSM RNSM p-value b
(n = 270) (n = 41)
Hospital stay (days) 12 ± 3 14 ± 4 0.001 c
Total operation time (min) 303.9 ± 195.9 308.9 ± 75.5 < 0.001 c
Mastectomy time (min) 104.5 ± 40.5 181.5 ± 44.7 < 0.001 c
Console time (min) 64 ± 40
Reconstruction time (min) 196.8 ± 182.5 140.5 ± 52.5 0.019 c
Operation site Left 139 (51.5) 19 (46.3) 0.616
Right 131 (48.5) 22 (53.7)
Reconstruction types T/E 190 (70.4) 21 (51.2) < 0.001
DTI 5 (1.9) 20 (48.8)
TRAM 73 (27.0) 0 (0.0)
LD 2 (0.7) 0 (0.0)
Incision types IMF 51 (18.9) 0 (0.0) < 0.001
Radial 32 (11.9) 0 (0.0)
Upper-periareolar with extension 120 (44.4) 0 (0.0)
Lower-periareolar with extension 52 (19.3) 0 (0.0)
Circumareolar 3 (1.1) 0 (0.0)
Elliptical 12 (4.4) 0 (0.0)
Lateral or axillary 0 (0.0) 41 (100.0)
SLNB a No 20 (7.7) 2 (5.9) > 0.99
Yes 239 (92.3) 32 (94.1)
ALND a No 224 (86.5) 31 (91.2) 0.592
Yes 35 (13.5) 3 (8.8)
Margin status a No 245 (98.8) 33 (97.1) 0.423
Yes 3 (1.2) 1 (2.9)

Values are represented as mean ± SD or number (percentage). ALND, axillary lymph node dissection; CNSM, conventional nipple-sparing mastectomy; DTI, direct-to-implant; IMF, inframammary fold; LD, latissimus dorsi flap; RNSM, robot-assisted nipple-sparing mastectomy; SLNB, sentinel lymph node biopsy; T/E, tissue expander; TRAM, transverse rectus abdominis musculocutaneous flap.

a

29 cases of benign disease or BRCA mutation carriers were not included (n = 282).

b

Chi-square test or Fisher’s exact test.

c

Student’s t test or Mann Whitney test.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES